<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35072888</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>24</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>24</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1865-8652</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>39</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Advances in therapy</Title>
          <ISOAbbreviation>Adv Ther</ISOAbbreviation>
        </Journal>
        <ArticleTitle>A Review of the Unique Drug Development Strategy of Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate: A First-in-Class, Once-Daily, Single-Inhaler, Fixed-Dose Combination Treatment for Asthma.</ArticleTitle>
        <Pagination>
          <StartPage>2365</StartPage>
          <EndPage>2378</EndPage>
          <MedlinePgn>2365-2378</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s12325-021-02025-w</ELocationID>
        <Abstract>
          <AbstractText>A novel, once-daily (o.d.), fixed-dose combination (FDC) of indacaterol acetate (IND), glycopyrronium bromide (GLY), and mometasone furoate (MF), delivered by the inhaler Breezhaler<sup>®</sup> device, is the first long-acting beta2-adrenergic agonist/long-acting muscarinic antagonist/inhaled corticosteroid (LABA/LAMA/ICS) therapy to be approved for maintenance treatment of asthma in adults inadequately controlled on LABA/ICS. The approval of IND/GLY/MF in the European Union (EU) also included an optional electronic sensor and smartphone (or other suitable device) application, making it the first "digital companion" that can be prescribed with an asthma medication. As a result, the European Medicines Agency included this approval as one of the "outstanding contributions to public health" (for Pneumology/Allergology) in their 2020 highlights report. Alongside IND/GLY/MF, an o.d. LABA/ICS FDC, IND/MF, was also developed and approved. This review outlines the unique strategy used in the accelerated development of IND/GLY/MF that combined various approaches: (1) selecting individual components with established efficacy/safety, (2) bridging doses to optimize efficacy/safety of IND/GLY/MF and IND/MF delivered via the Breezhaler<sup>®</sup> device, (3) developing IND/GLY/MF and IND/MF in parallel, and (4) submission for regulatory approval before formal completion of the pivotal phase III studies. IND/GLY/MF and IND/MF were combined in a single-development plan (PLATINUM program), which comprised four phase III studies: QUARTZ and PALLADIUM evaluated IND/MF while IRIDIUM and ARGON evaluated IND/GLY/MF. A unique feature was the inclusion of two LABA/ICS comparators in the pivotal IRIDIUM study-IND/MF as an internal comparator, and high-dose salmeterol xinafoate/fluticasone propionate (SAL/FLU) as a marketed comparator. In the ARGON study, IND/GLY/MF was compared against o.d. tiotropium (via Respimat<sup>®</sup>) plus twice-daily (b.i.d.) high-dose SAL/FLU (via Diskus<sup>®</sup>). As a result of this development strategy, the development and approval of IND/GLY/MF was accelerated by ca. 4 years as against what would be expected from a traditional approach, novel data were generated, and a unique optional digital companion was approved in the EU. A Video Abstract by Dr Dominic Brittain, Global Drug Development, Novartis. (MP4 228293 kb).</AbstractText>
          <CopyrightInformation>© 2022. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Brittain</LastName>
            <ForeName>Dominic</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Novartis Pharma AG, Basel, Switzerland. dominic.brittain@novartis.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>D'Andrea</LastName>
            <ForeName>Peter</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gruen</LastName>
            <ForeName>Emilie</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Novartis Pharma AG, Basel, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hosoe</LastName>
            <ForeName>Motoi</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Novartis Pharma AG, Basel, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jain</LastName>
            <ForeName>Devendra</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Novartis Pharma AG, Basel, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jauernig</LastName>
            <ForeName>Juergen</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Novartis Pharma AG, Basel, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pethe</LastName>
            <ForeName>Abhijit</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Scosyrev</LastName>
            <ForeName>Emil</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tanase</LastName>
            <ForeName>Ana-Maria</ForeName>
            <Initials>AM</Initials>
            <AffiliationInfo>
              <Affiliation>Novartis Pharma AG, Basel, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tillmann</LastName>
            <ForeName>Hanns-Christian</ForeName>
            <Initials>HC</Initials>
            <AffiliationInfo>
              <Affiliation>Novartis Institutes for Biomedical Research, Translational Medicine, Basel, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
          <PublicationType UI="D059040">Video-Audio Media</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>01</Month>
          <Day>24</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Adv Ther</MedlineTA>
        <NlmUniqueID>8611864</NlmUniqueID>
        <ISSNLinking>0741-238X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000085">Acetates</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D058666">Adrenergic beta-2 Receptor Agonists</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001993">Bronchodilator Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007189">Indans</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D015363">Quinolones</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>04201GDN4R</RegistryNumber>
          <NameOfSubstance UI="D000068656">Mometasone Furoate</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>44448S9773</RegistryNumber>
          <NameOfSubstance UI="D007495">Iridium</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>67XQY1V3KH</RegistryNumber>
          <NameOfSubstance UI="D001128">Argon</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>8OR09251MQ</RegistryNumber>
          <NameOfSubstance UI="C510790">indacaterol</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>V92SO9WP2I</RegistryNumber>
          <NameOfSubstance UI="D006024">Glycopyrrolate</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000085" MajorTopicYN="N">Acetates</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000280" MajorTopicYN="N">Administration, Inhalation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058666" MajorTopicYN="N">Adrenergic beta-2 Receptor Agonists</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001128" MajorTopicYN="N">Argon</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001249" MajorTopicYN="Y">Asthma</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001993" MajorTopicYN="N">Bronchodilator Agents</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000076722" MajorTopicYN="N">Drug Development</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006024" MajorTopicYN="N">Glycopyrrolate</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007189" MajorTopicYN="N">Indans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007495" MajorTopicYN="N">Iridium</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000068656" MajorTopicYN="N">Mometasone Furoate</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009330" MajorTopicYN="N">Nebulizers and Vaporizers</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D029424" MajorTopicYN="Y">Pulmonary Disease, Chronic Obstructive</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015363" MajorTopicYN="N">Quinolones</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Accelerated development strategy</Keyword>
        <Keyword MajorTopicYN="N">Asthma</Keyword>
        <Keyword MajorTopicYN="N">Digital companion</Keyword>
        <Keyword MajorTopicYN="N">Indacaterol acetate/glycopyrronium bromide/mometasone furoate</Keyword>
        <Keyword MajorTopicYN="N">LABA/LAMA/ICS</Keyword>
        <Keyword MajorTopicYN="N">Once daily</Keyword>
        <Keyword MajorTopicYN="N">Single inhaler</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>24</Day>
          <Hour>12</Hour>
          <Minute>14</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35072888</ArticleId>
        <ArticleId IdType="pmc">PMC9122880</ArticleId>
        <ArticleId IdType="doi">10.1007/s12325-021-02025-w</ArticleId>
        <ArticleId IdType="pii">10.1007/s12325-021-02025-w</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Enerzair® Breezhaler®. Summary of product characteristics (SmPC). Last updated 12 May 2021. https://www.medicines.org.uk/emc/product/11886/smpc#gref. Accessed 26 Sept 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Atectura® Breezhaler®. Summary of product characteristics (SmPC). Last updated 11 Aug 2021. https://www.medicines.org.uk/emc/product/11885/smpc. Accessed 26 Sept 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Novartis receives EC approval for Enerzair® Breezhaler®, including the first digital companion (sensor and app) that can be prescribed alongside a treatment for uncontrolled asthma in the EU. Media Release. https://www.novartis.com/news/media-releases/novartis-receives-ec-approval-enerzair-breezhaler-including-first-digital-companion-sensor-and-app-can-be-prescribed-alongside-treatment-uncontrolled-asthma-eu. Accessed 26 Sept 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>EMA’s transformative treatments of 2020. https://www.europeanpharmaceuticalreview.com/article/143977/emas-transformative-treatments-of-2020/. Accessed 26 Sept 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Katsaounou P, Odemyr M, Spranger O, et al.  Still fighting for breath: a patient survey of the challenges and impact of severe asthma. ERJ Open Res. 2018;4:00076–2018. doi: 10.1183/23120541.00076-2018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1183/23120541.00076-2018</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peters SP, Ferguson G, Deniz Y, Reisner C. Uncontrolled asthma: a review of the prevalence, disease burden and options for treatment. Respir Med. 2006;100:1139–1151. doi: 10.1016/j.rmed.2006.03.031.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.rmed.2006.03.031</ArticleId>
            <ArticleId IdType="pubmed">16713224</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Price D, Fletcher M, van der Molen T. Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey. NPJ Prim Care Respir Med. 2014;24:14009. doi: 10.1038/npjpcrm.2014.9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/npjpcrm.2014.9</ArticleId>
            <ArticleId IdType="pmc">PMC4373302</ArticleId>
            <ArticleId IdType="pubmed">24921985</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Global Initiative for Asthma. Global strategy for asthma management and prevention. 2021. http://www.ginasthma.org. Accessed 26 Sept 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Makela MJ, Backer V, Hedegaard M, Larsson K. Adherence to inhaled therapies, health outcomes and costs in patients with asthma and COPD. Respir Med. 2013;107:1481–1490. doi: 10.1016/j.rmed.2013.04.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.rmed.2013.04.005</ArticleId>
            <ArticleId IdType="pubmed">23643487</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murphy KR, Bender BG. Treatment of moderate to severe asthma: patient perspectives on combination inhaler therapy and implications for adherence. J Asthma Allergy. 2009;2:63–72. doi: 10.2147/JAA.S4214.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/JAA.S4214</ArticleId>
            <ArticleId IdType="pmc">PMC3048599</ArticleId>
            <ArticleId IdType="pubmed">21437145</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Engelkes M, Janssens HM, de Jongste JC, Sturkenboom MC, Verhamme KM. Medication adherence and the risk of severe asthma exacerbations: a systematic review. Eur Respir J. 2015;45:396–407. doi: 10.1183/09031936.00075614.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1183/09031936.00075614</ArticleId>
            <ArticleId IdType="pubmed">25323234</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Greene G, Costello RW. Personalizing medicine—could the smart inhaler revolutionize treatment for COPD and asthma patients? Expert Opin Drug Deliv. 2019;16:675–677. doi: 10.1080/17425247.2019.1628017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/17425247.2019.1628017</ArticleId>
            <ArticleId IdType="pubmed">31177857</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johnson N, Varughese B, De La Torre MA, Surani SR, Udeani G. A review of respiratory biologic agents in severe asthma. Cureus. 2019;11:e5690.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6830845</ArticleId>
            <ArticleId IdType="pubmed">31728232</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barnes PJ, Bonini S, Seeger W, Belvisi MG, Ward B, Holmes A. Barriers to new drug development in respiratory disease. Eur Respir J. 2015;45:1197–1207. doi: 10.1183/09031936.00007915.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1183/09031936.00007915</ArticleId>
            <ArticleId IdType="pubmed">25931481</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Onbrez Breezhaler 150 microgram inhalation powder, hard capsules. Summary of product characteristics (SmPC). Last updated 08 Jan 2021. https://www.medicines.org.uk/emc/product/7794/smpc. Accessed 26 Sept 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Zafar MA, Droege C, Foertsch M, Panos RJ. Update on ultra-long-acting beta agonists in chronic obstructive pulmonary disease. Expert Opin Investig Drugs. 2014;23(12):1687–1701. doi: 10.1517/13543784.2014.942730.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1517/13543784.2014.942730</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seebri Breezhaler 44 micrograms inhalation powder, hard capsules. Summary of product characteristics (SmPC). Last updated 09 Jan 2020. https://www.medicines.org.uk/emc/product/2840. Accessed 26 Sept 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Ultibro Breezhaler 85 micrograms/43 micrograms inhalation powder hard capsules. Summary of product characteristics. Last updated 04 Dec 2020. https://www.medicines.org.uk/emc/product/3496. Accessed 26 Sept 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Hansel TT, Neighbour H, Erin EM, et al.  Glycopyrrolate causes prolonged bronchoprotection and bronchodilatation in patients with asthma. Chest. 2005;128(4):1974–1979. doi: 10.1378/chest.128.4.1974.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1378/chest.128.4.1974</ArticleId>
            <ArticleId IdType="pubmed">16236844</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pearlman DS, Greos L, LaForce C, Orevillo CJ, Owen R, Higgins M. Bronchodilator efficacy of indacaterol, a novel once-daily beta2-agonist, in patients with persistent asthma. Ann Allergy Asthma Immunol. 2008;101(1):90–95. doi: 10.1016/S1081-1206(10)60840-X.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1081-1206(10)60840-X</ArticleId>
            <ArticleId IdType="pubmed">18681090</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McCormack PL, Plosker GL. Inhaled mometasone furoate: a review of its use in persistent asthma in adults and adolescents. Drugs. 2006;66(8):1151–1168. doi: 10.2165/00003495-200666080-00011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2165/00003495-200666080-00011</ArticleId>
            <ArticleId IdType="pubmed">16789800</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tan RA, Corren J. Mometasone furoate in the management of asthma: a review. Ther Clin Risk Manag. 2008;4(6):1201–1208.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2643101</ArticleId>
            <ArticleId IdType="pubmed">19337427</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Asmanex Twisthaler 400 micrograms Inhalation Powder. Summary of product characteristics. Last updated 17 Feb 2021. https://www.medicines.org.uk/emc/product/6753/smpc. Accessed 26 Sept 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Clinicaltrials.gov. Efficacy, safety and pharmacokinetics of indacaterol acetate in patients with persistent asthma (CQMF149E2203). Last updated 27 Jan 2015. https://www.clinicaltrials.gov/ct2/show/results/NCT01609478?term=CQMF149E2203&amp;draw=2&amp;rank=1. Accessed 26 Sept 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Miller D, Vaidya S, Jauernig J, et al.  Lung function, pharmacokinetics, and tolerability of inhaled indacaterol maleate and acetate in asthma patients. Respir Res. 2020;21(1):248. doi: 10.1186/s12931-020-01501-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12931-020-01501-1</ArticleId>
            <ArticleId IdType="pmc">PMC7513528</ArticleId>
            <ArticleId IdType="pubmed">32967685</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seebri Breezhaler. Summary of product characteristics (SmPC). Last updated 09 Jan 2020. https://www.medicines.org.uk/emc/product/2840. Accessed 26 Sept 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Vaidya S, Ziegler D, Tanase AM, et al.  Pharmacokinetics of mometasone furoate delivered via two dry powder inhalers. Pulm Pharmacol Ther. 2021;70:102019. doi: 10.1016/j.pupt.2021.102019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pupt.2021.102019</ArticleId>
            <ArticleId IdType="pubmed">33771722</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Buhl R, Nikolaev I, Tillmann HC, et al.  Dose bridging data for mometasone furoate in once-daily fixed-dose inhaled combinations of mometasone furoate/indacaterol and mometasone furoate/indacaterol/glycopyrronium in patients with asthma. Pulm Pharmacol Ther. 2021;70:102068. doi: 10.1016/j.pupt.2021.102068.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pupt.2021.102068</ArticleId>
            <ArticleId IdType="pubmed">34329722</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Buhl R, Tanase AM, Hosoe M, et al.  A randomized, double-blind study to compare the efficacy and safety of two doses of mometasone furoate delivered via Breezhaler® or Twisthaler® in patients with asthma. Pulm Pharmacol Ther. 2020;62:101919. doi: 10.1016/j.pupt.2020.101919.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pupt.2020.101919</ArticleId>
            <ArticleId IdType="pubmed">32387408</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vaidya SS, Khindri S, Calder N, et al.  Pharmacokinetics of indacaterol and mometasone furoate delivered alone or in a free or fixed dose combination in healthy subjects. Pulm Pharmacol Ther. 2016;37:30–36. doi: 10.1016/j.pupt.2016.01.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pupt.2016.01.004</ArticleId>
            <ArticleId IdType="pubmed">26845343</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dal Negro RW. Dry powder inhalers and the right things to remember: a concept review. Multidiscip Respir Med. 2015;10(1):13. doi: 10.1186/s40248-015-0012-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40248-015-0012-5</ArticleId>
            <ArticleId IdType="pmc">PMC4397837</ArticleId>
            <ArticleId IdType="pubmed">25878791</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Panigone S, Sandri F, Ferri R, Volpato A, Nudo E, Nicolini G. Environmental impact of inhalers for respiratory diseases: decreasing the carbon footprint while preserving patient-tailored treatment. BMJ Open Respir Res. 2020;7(1):e000571. doi: 10.1136/bmjresp-2020-000571.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmjresp-2020-000571</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aumônier S, Whiting A, Norris S, Collins M, Coleman T, Fulford B, Breitmayer E. Carbon footprint assessment of Breezhaler® dry powder inhaler. Drug Delivery to the Lungs. Vol. 31. 2020. https://ddl-conference.com/ddl2020-christmas-lectures/conference-papers/carbon-footprint-assessment-ofbreezhaler-dry-powder-inhaler/</Citation>
        </Reference>
        <Reference>
          <Citation>Hillman T, Mortimer F, Hopkinson NS. Inhaled drugs and global warming: time to shift to dry powder inhalers. BMJ. 2013;346:f3359. doi: 10.1136/bmj.f3359.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmj.f3359</ArticleId>
            <ArticleId IdType="pubmed">23714412</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gessner C, Kornmann O, Maspero J, et al.  Fixed-dose combination of indacaterol/glycopyrronium/mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: a randomised, phase IIIb, non-inferiority study (ARGON) Respir Med. 2020;170:106021. doi: 10.1016/j.rmed.2020.106021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.rmed.2020.106021</ArticleId>
            <ArticleId IdType="pubmed">32843164</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kerstjens HAM, Maspero J, Chapman KR, et al.  Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study. Lancet Respir Med. 2020;8(10):1000–1012. doi: 10.1016/S2213-2600(20)30190-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S2213-2600(20)30190-9</ArticleId>
            <ArticleId IdType="pubmed">32653074</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kornmann O, Mucsi J, Kolosa N, et al.  Efficacy and safety of inhaled once-daily low-dose indacaterol acetate/mometasone furoate in patients with inadequately controlled asthma: phase III randomised QUARTZ study findings. Respir Med. 2020;161:105809. doi: 10.1016/j.rmed.2019.105809.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.rmed.2019.105809</ArticleId>
            <ArticleId IdType="pubmed">32056721</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van Zyl-Smit RN, Krüll M, Gessner C, et al.  Once-daily mometasone plus indacaterol versus mometasone or twice-daily fluticasone plus salmeterol in patients with inadequately controlled asthma (PALLADIUM): a randomised, double-blind, triple-dummy, controlled phase 3 study. Lancet Respir Med. 2020;8(10):987–999. doi: 10.1016/S2213-2600(20)30178-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S2213-2600(20)30178-8</ArticleId>
            <ArticleId IdType="pubmed">32653075</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scosyrev E, van Zyl-Smit R, Kerstjens H, et al.  Cardiovascular safety of mometasone/indacaterol and mometasone/indacaterol/glycopyrronium once-daily fixed-dose combinations in asthma: pooled analysis of phase 3 trials. Respir Med. 2021;180:106311. doi: 10.1016/j.rmed.2021.106311.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.rmed.2021.106311</ArticleId>
            <ArticleId IdType="pubmed">33711782</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>European Commission. Union Register of medicinal products for human use—Enerzair Breezhaler. Last updated 27 July 2021. https://ec.europa.eu/health/documents/community-register/html/h1438.htm. Last accessed 24 Sept 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Novartis receives simultaneous approval for five new products from Japanese Ministry of Health, Labour and Welfare, offering Japanese patients a broad range of novel treatment options. Press release. https://www.globenewswire.com/en/news-release/2020/06/29/2054449/0/en/Novartis-receives-simultaneous-approval-for-five-new-products-from-Japanese-Ministry-of-Health-Labour-and-Welfare-offering-Japanese-patients-a-broad-range-of-novel-treatment-option.html. Last accessed 24 July 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>European Commission. Union Register of medicinal products for human use—Atectura Breezhaler. Last updated 26 Apr 2021. https://ec.europa.eu/health/documents/community-register/html/h1439.htm. Last accessed 24 July 2021.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
